ClinicalTrials.Veeva

Menu

Novel Lenses for Myopia Progression Trial

S

Shanghai Eye Disease Prevention and Treatment Center

Status

Active, not recruiting

Conditions

Myopia, Progressive

Treatments

Other: single vision lens
Other: spectacle lens

Study type

Interventional

Funder types

Other

Identifiers

NCT06563700
2024-002

Details and patient eligibility

About

This is a multi-center , prospective, randomised, longitudinal study to evaluate rate of myopia progression with novel lenses compared to Single-Vision spectacles. A total of 342 children will be recruited where 57 participants each are randomised to wear one of 5 test spectacle lens designs or a single vision lens (control) for 12 months. At the end of 12 months, those randomised to single vision lenses will be transferred to one of the test lenses and all the groups continued for another 12 months. Myopia progression during the second year with test lenses will be compared to historical or published controls.

Enrollment

300 estimated patients

Sex

All

Ages

7 to 13 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

be accompanied by a parent or guardian who is able to read and comprehend Chinese/English and sign a record of informed consent/assent; at baseline, be within the age range of 7 to 13 years old inclusive; be diagnosed as myopic having cycloplegic spherical equivalent between -0.75 dioptre (D) and -5.00 dioptre (D); astigmatism ≤1.50D; anisometropia of not more than 1.50D; be willing to comply with the wearing of clinical trial spectacles and clinical trial visit schedule as directed by the investigator; have ocular findings deemed to be normal; vision correctable to at least 0.8 or better in each eye with spectacles.

Exclusion criteria

Any pre-existing systemic or ocular condition, including infection or disease that is likely to affect visual acuity and refractive error; Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto-immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants.

Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant's ocular health / physiology in an adverse or beneficial manner at enrolment and/or during the clinical trial.

History of eye trauma Amblyopia Strabismus History of use of myopia control interventions such as Orthokeratology, atropine or eye surgery 6 months prior to commencement of this trial.

Known allergy or intolerance to ingredients to cycloplegic eye-drops. Currently enrolled in another clinical trial.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

300 participants in 6 patient groups, including a placebo group

Group A
Placebo Comparator group
Description:
single vision lens
Treatment:
Other: spectacle lens
Other: single vision lens
Group B
Experimental group
Description:
one of ZEISS BD spectacle lens designs 1 to 5
Treatment:
Other: spectacle lens
Group C
Experimental group
Description:
one of ZEISS BD spectacle lens designs 1 to 5
Treatment:
Other: spectacle lens
Group D
Experimental group
Description:
one of ZEISS BD spectacle lens designs 1 to 5
Treatment:
Other: spectacle lens
Group E
Experimental group
Description:
one of ZEISS BD spectacle lens designs 1 to 5
Treatment:
Other: spectacle lens
Group F
Experimental group
Description:
one of ZEISS BD spectacle lens designs 1 to 5
Treatment:
Other: spectacle lens

Trial contacts and locations

1

Loading...

Central trial contact

Xiangui He

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems